CytoDyn says it plans to acquire ProstaGene

16 July 2018

USA-based biotech CytoDyn (OTCQB:CYDY) says it has signed a non-binding letter of intent regarding a proposed acquisition of intellectual property and other assets of ProstaGene, a privately held company focused on prostate cancer diagnostics and therapeutics aimed at blocking cancer metastasis by blocking CCR5.

At the same time, the company remains committed to advancing its clinical programs with PRO 140 in HIV and graft-versus-host disease (GvHD), and is continuing with its previously announced plans to submit a Biologics License Application to the US Food and Drug Administration for PRO 140 as a combination therapy for HIV.

As part of the proposed transaction with ProstaGene, Dr Richard Pestell, the chief executive of ProstaGene and president of the Pennsylvania Cancer and Regenerative Medicine Research Center, will join the company as chief medical officer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK